Pfizer is currently trading at a low forward earnings multiple of 9.1x and offers a compelling 6.7% dividend yield, making it materially undervalued. The company is facing fewer losses from patent expirations than previously expected, with management now forecasting $14–15 billion in losses, easing long-term revenue concerns. Pfizer's recent product launches and acquisitions are driving strong operational growth of 22%, supported by a robust pipeline especially in oncology and weight loss. The analyst maintains a Buy rating, highlighting Pfizer's recovery signals, strong free cash flow, and focus on business development and dividends, recommending it as an attractive healthcare investment opportunity.
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU, an oral PROTAC drug for advanced breast cancer. The FDA recently approved VEPPANU for estrogen receptor-positive, ...
Nvidia's market capitalization recently exceeded $5.3 trillion, surpassing the combined value of all 59 healthcare companies in the S&P 500, which total about $5.2 trillion. This shift highlights the massive investor confidence in AI infrastructure, ...
Warren Buffett's investment approach focuses on buying durable, cash-generating companies at reasonable prices, with several current Berkshire Hathaway holdings trading below $30. Stocks like Kraft Heinz, Sirius XM, and Liberty Latin America fit this...
Arvinas and Pfizer have entered a licensing deal with Rigel Pharmaceuticals granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU, the first FDA-approved PROTAC drug for certain advanced breast cancers. The deal in...
Rigel Pharmaceuticals has secured exclusive global rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for advanced ER+/HER2-, ESR1-mutated breast cancer. The drug showed a significant progres...
